| 2:40 PM | Modulation of DAPT Duration: Risk-benefit of 1-year DAPT Lecturer: Tullio Palmerini |
| 2:48 PM | Clopidogrel Monotherapy After Short-term DAPT in Patients who Underwent PCI using DES Lecturer: Takeshi Kimura |
| 2:56 PM | P2Y12 Inhibitor or Asprin for Long-term Antiplatelet Management Lecturer: Kyung Woo Park |
| 3:04 PM | Recommendation, Guided vs. Potent P2Y12 Inhibitor Therapy: Updated Evidence Lecturer: Pieter Smits |
| 3:12 PM | Panel Discussion I |
| 3:22 PM | Edoxaban vs. DAPT for Valve Thrombosis and Cerebral Thromboembolism After TAVR: Deep-Dive into ADAPT-TAVR Trial Lecturer: Duk-Woo Park |
| 3:30 PM | Updated Evidence and Recommendation of Antithrombotic Therapy after TAVR Lecturer: George D. Dangas |
| 3:38 PM | Next Novel Antithrombotic Drugs for ACS/PCI: Oral Factor XIa inhibitor or More Lecturer: Roxana Mehran |
| 3:46 PM | BRIGHT-4 Trial; Bivalirudin with a Post-PCI High-Dose Infusion vs. Heparin Monotherapy During Primary PCI in STEMI Lecturer: Gregg W. Stone |
| 3:54 PM | Panel Discussion II |